Institution
Rush University Medical Center
Healthcare•Chicago, Illinois, United States•
About: Rush University Medical Center is a healthcare organization based out in Chicago, Illinois, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 13915 authors who have published 29027 publications receiving 1379216 citations. The organization is also known as: Rush Presbyterian St. Luke's Medical Center.
Topics: Population, Medicine, Dementia, Transplantation, Health care
Papers published on a yearly basis
Papers
More filters
••
Tulane University1, Colorado State University2, University of Tübingen3, Applied Science Private University4, Université de Montréal5, United Arab Emirates University6, Rush University Medical Center7, Baylor College of Medicine8, Mount Sinai St. Luke's and Mount Sinai Roosevelt9, Nara Medical University10, National Technical University of Athens11, University of Illinois at Urbana–Champaign12, Creighton University13, Shanmugha Arts, Science, Technology & Research Academy14, University of Rome Tor Vergata15, Purdue University16, Wayne State University17, University of Glasgow18, New York Medical College19, Mayo Clinic20
TL;DR: The advances made toward understanding the basis of cancer immune evasion are discussed, the efficacy of various therapeutic measures and targets that have been developed or are being investigated to enhance tumor rejection are summarized and some natural agents and phytochemicals merit further study.
1,064 citations
••
TL;DR: Study of lipopolysaccharide and cytokine levels in 97 patients with the sepsis syndrome found a positive correlation between high levels of plasma TNF- and mortality, and implicate T NF- as an important mediator in sepsi.
Abstract: Objective: To determine whether plasma tumor necrosis factor- (TNF-), interleukin-1 (IL-1 ), interleukin-6 (IL-6), and lipopolysaccharide are detectable in patients when they first present with the...
1,062 citations
••
TL;DR: The objective of this work was to update previous EBM reviews on treatments for PD with a focus on non‐motor symptoms and found that most of the other interventions there is insufficient evidence to make adequate conclusions on their efficacy.
Abstract: The Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on motor symptoms of PD. In this revised version the MDS task force decided it was necessary to extend the review to non-motor symptoms. The objective of this work was to update previous EBM reviews on treat- ments for PD with a focus on non-motor symptoms. Level-I (randomized controlled trial, RCT) reports of pharmacological and nonpharmacological interventions for the non-motor symptoms of PD, published as full
1,061 citations
••
TL;DR: Dietary intake of n-3 polyunsaturated fatty acids and weekly consumption of fish may reduce the risk of incident Alzheimer disease.
Abstract: Background Dietary n-3 polyunsaturated fatty acids improve brain functioning in animal studies, but there is limited study of whether this type of fat protects against Alzheimer disease. Objective To examine whether fish consumption and intake of different types of n-3 fatty acids protect against Alzheimer disease. Design Prospective study conducted from 1993 through 2000, of a stratified random sample from a geographically defined community. Participants were followed up for an average of 3.9 years for the development of Alzheimer disease. Patients A total of 815 residents, aged 65 to 94 years, who were initially unaffected by Alzheimer disease and completed a dietary questionnaire on average 2.3 years before clinical evaluation of incident disease. Main Outcome Measure Incident Alzheimer disease diagnosed in a structured neurologic examination by means of standardized criteria. Results A total of 131 sample participants developed Alzheimer disease. Participants who consumed fish once per week or more had 60% less risk of Alzheimer disease compared with those who rarely or never ate fish (relative risk, 0.4; 95% confidence interval, 0.2-0.9) in a model adjusted for age and other risk factors. Total intake of n-3 polyunsaturated fatty acids was associated with reduced risk of Alzheimer disease, as was intake of docosahexaenoic acid (22:6n-3). Eicosapentaenoic acid (20:5n-3) was not associated with Alzheimer disease. The associations remained unchanged with additional adjustment for intakes of other dietary fats and of vitamin E and for cardiovascular conditions. Conclusion Dietary intake of n-3 fatty acids and weekly consumption of fish may reduce the risk of incident Alzheimer disease.
1,054 citations
••
Yeshiva University1, Wayne State University2, University of Florida3, University of North Carolina at Chapel Hill4, Fred Hutchinson Cancer Research Center5, National Institutes of Health6, Medical College of Wisconsin7, Rush University Medical Center8, Rutgers University9, George Washington University10, Ohio State University11
TL;DR: Excess risk for all strokes attributed to estrogen plus progestin appeared to be present in all subgroups of women examined, and excess risk of all stroke was apparent in all age groups, in all categories of baseline stroke risk, and in women with and without hypertension, prior history of cardiovascular disease, use of hormones, statins, or aspirin.
Abstract: ContextThe Women's Health Initiative (WHI) trial of estrogen plus progestin
was stopped early because of adverse effects, including an increased risk
of stroke in the estrogen plus progestin group.ObjectiveTo assess the effect of estrogen plus progestin on ischemic and hemorrhagic
stroke and in subgroups, and to determine whether the effect of estrogen plus
progestin was modified by baseline levels of blood biomarkers.DesignMulticenter double-blind, placebo-controlled, randomized clinical trial
involving 16 608 women aged 50 through 79 years with an average follow-up
of 5.6 years. Baseline levels of blood-based markers of inflammation, thrombosis,
and lipid levels were measured in the first 140 centrally confirmed stroke
cases and 513 controls.InterventionsParticipants received 0.625 mg/d of conjugated equine estrogen plus
2.5 mg/d of medroxyprogesterone acetate (n = 8506) or placebo (n = 8102).Main Outcome MeasuresOverall strokes and stroke subtype and severity were centrally adjudicated
by stroke neurologists.ResultsOne hundred fifty-one patients (1.8%) in the estrogen plus progestin
and 107 (1.3%) in the placebo groups had strokes. Overall 79.8% of strokes
were ischemic. For combined ischemic and hemorrhagic strokes, the intention-to-treat
hazard ratio (HR) for estrogen plus progestin vs placebo was 1.31 (95% confidence
interval [CI], 1.02-1.68); with adjustment for adherence, the HR was 1.50
(95% CI, 1.08-2.08). The HR for ischemic stroke was 1.44 (95% CI, 1.09-1.90)
and for hemorrhagic stroke, 0.82 (95% CI, 0.43-1.56). Point estimates of the
HRs indicate that excess risk of all stroke was apparent in all age groups,
in all categories of baseline stroke risk, and in women with and without hypertension,
prior history of cardiovascular disease, use of hormones, statins, or aspirin.
Other risk factors for stroke, including smoking, blood pressure, diabetes,
lower use of vitamin C supplements, blood-based biomarkers of inflammation,
higher white blood cell count, and higher hematocrit levels did not modify
the effect of estrogen plus progestin on stroke risk.ConclusionsEstrogen plus progestin increases the risk of ischemic stroke in generally
healthy postmenopausal women. Excess risk for all strokes attributed to estrogen
plus progestin appeared to be present in all subgroups of women examined.
1,052 citations
Authors
Showing all 14032 results
Name | H-index | Papers | Citations |
---|---|---|---|
John Q. Trojanowski | 226 | 1467 | 213948 |
Virginia M.-Y. Lee | 194 | 993 | 148820 |
Luigi Ferrucci | 193 | 1601 | 181199 |
David A. Bennett | 167 | 1142 | 109844 |
Todd R. Golub | 164 | 422 | 201457 |
David Cella | 156 | 1258 | 106402 |
M.-Marsel Mesulam | 150 | 558 | 90772 |
John D. E. Gabrieli | 142 | 480 | 68254 |
David J. Kupfer | 141 | 862 | 102498 |
Clifford B. Saper | 136 | 406 | 72203 |
Pasi A. Jänne | 136 | 685 | 89488 |
Nikhil C. Munshi | 134 | 906 | 67349 |
Martin B. Keller | 131 | 541 | 65069 |
Michael E. Thase | 131 | 923 | 75995 |
Steven R. Simon | 129 | 1090 | 80331 |